Eli Lilly and Company $LLY Stake Boosted by Harold Davidson & Associates Inc.

Harold Davidson & Associates Inc. lifted its stake in Eli Lilly and Company (NYSE:LLY) by 44.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 4,599 shares of the company’s stock after acquiring an additional 1,417 shares during the quarter. Eli Lilly and Company makes up 1.6% of Harold Davidson & Associates Inc.’s portfolio, making the stock its 16th biggest holding. Harold Davidson & Associates Inc.’s holdings in Eli Lilly and Company were worth $3,509,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of LLY. Redmont Wealth Advisors LLC purchased a new position in Eli Lilly and Company in the third quarter valued at about $39,000. Syon Capital LLC lifted its holdings in shares of Eli Lilly and Company by 10.1% during the 3rd quarter. Syon Capital LLC now owns 13,253 shares of the company’s stock valued at $10,112,000 after buying an additional 1,212 shares during the last quarter. Advisors Capital Management LLC grew its stake in shares of Eli Lilly and Company by 6.4% in the 3rd quarter. Advisors Capital Management LLC now owns 10,551 shares of the company’s stock valued at $8,051,000 after buying an additional 630 shares in the last quarter. Jacobi Capital Management LLC grew its stake in shares of Eli Lilly and Company by 5.6% in the 3rd quarter. Jacobi Capital Management LLC now owns 14,566 shares of the company’s stock valued at $11,114,000 after buying an additional 766 shares in the last quarter. Finally, Hodges Capital Management Inc. increased its holdings in Eli Lilly and Company by 7.4% in the third quarter. Hodges Capital Management Inc. now owns 11,635 shares of the company’s stock worth $8,877,000 after buying an additional 800 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Down 1.4%

Eli Lilly and Company stock opened at $1,021.53 on Thursday. The company has a debt-to-equity ratio of 1.54, a current ratio of 1.58 and a quick ratio of 1.19. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,133.95. The firm has a fifty day moving average price of $1,054.92 and a two-hundred day moving average price of $913.16. The firm has a market cap of $963.67 billion, a price-to-earnings ratio of 44.51, a P/E/G ratio of 1.21 and a beta of 0.39.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The company had revenue of $19.29 billion for the quarter, compared to the consensus estimate of $17.85 billion. During the same period last year, the business posted $5.32 earnings per share. The firm’s revenue was up 42.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date is Friday, February 13th. Eli Lilly and Company’s dividend payout ratio is presently 30.15%.

Analyst Ratings Changes

Several analysts have commented on LLY shares. Jefferies Financial Group boosted their target price on shares of Eli Lilly and Company from $976.00 to $1,300.00 and gave the stock a “buy” rating in a research report on Thursday, January 8th. Freedom Capital raised shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, February 10th. Sanford C. Bernstein reissued an “outperform” rating on shares of Eli Lilly and Company in a research report on Friday, December 19th. UBS Group restated a “buy” rating on shares of Eli Lilly and Company in a report on Monday, February 2nd. Finally, Guggenheim decreased their price target on Eli Lilly and Company from $1,163.00 to $1,161.00 and set a “buy” rating for the company in a research note on Tuesday, January 20th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $1,219.68.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly reported a first‑of‑its‑kind Phase 3b win showing its psoriasis drug Taltz (ixekizumab) plus Zepbound (tirzepatide) delivered superior efficacy — supports cross‑indication use and adds upside to Zepbound’s market opportunity. Lilly chalks up another trial win for Zepbound-Taltz combo in bid to break down psoriasis, obesity ‘silos’
• Positive Sentiment: Eli Lilly struck an exclusive licensing deal with CSL for clazakizumab (kidney disease indication), a deal worth up front and development consideration that broadens near‑term partnering and non‑GLP‑1 revenue potential. Eli Lilly Enters $100 Million Licensing Agreement with CSL Limited for Clazakizumab
• Positive Sentiment: Analysts raised their price target (Daiwa to $1,250) and the company’s recent EPS beat and FY‑2026 guidance remain supportive of multi‑year earnings growth. Daiwa Securities adjusts price target on Eli Lilly to $1,250
• Positive Sentiment: Medicare’s expansion of coverage for GLP‑1 weight‑loss drugs is easing pricing concerns and reduces a policy overhang that had pressured valuations. Eli Lilly and Company (LLY) Gains as Medicare Expansion of GLP-1 Weight Loss Drugs Eases Pricing Concerns
• Positive Sentiment: Retevmo showed promise in an adjuvant setting, expanding Lilly’s oncology franchise beyond core metabolic assets. Lilly scores rare cancer drug Retevmo adjuvant therapy
• Neutral Sentiment: Jim Cramer discussed Lilly and its weight‑loss drugs — a media boost but not a structural catalyst. Jim Cramer Discusses Eli Lilly (LLY) & Weight Loss Drugs
• Neutral Sentiment: Coverage pieces argue Lilly is leading the GLP‑1 race vs Novo Nordisk — bullish narrative but depends on trial, launch execution and pricing dynamics. Eli Lilly Trumps Novo Nordisk In GLP-1 Race
• Negative Sentiment: Analyst pieces highlight mounting competition in obesity (oral orforglipron, retatrutide and rivals) and the need for next‑gen launches to sustain growth — a valid risk to forecasts and valuation. Can LLY’s Next-Gen Obesity Pipeline Sustain Growth Amid Competition?

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.